Wonderland 2022 Recap: Mindstate Design Labs

The article Wonderland 2022 Recap: Mindstate Design Labs was originally published on Microdose.

With Wonderland 2022 still fresh in our rear-view mirrors, let’s take a moment to look at some of the highlights from the big event. Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, so let’s look at Mindstate Design Labs, a platinum sponsor for Wonderland: Miami 2022.

About Mindstate Design Labs

Launched out of Y Combinator in 2021, Mindstate Design Labs is a preclinical-stage psychedelic drug development company designing states of consciousness for mental health therapeutics. Recognizing the acute subjective experience of an altered state as central to treatment outcomes, the company is mapping the biological basis of the varieties of psychedelic experience. 

At Wonderland, Dillan DiNardo, CEO of  Mindstate Design Labs, took part in the following panels, adding insight and perspective from his company’s recent work.

• Ending the War on Drugs
• Intentional Design of Novel Modified Conscious States 

Mindstate Design Labs’ lead drug program is designed to produce an entactogenic state while minimizing the negative side effects and allowing for a greater number of treatment sessions. Phase I clinical trials are slated for 2023. 

The company’s lead program is followed by a pipeline of additional drug candidates designed to selectively produce various psychedelic effects for the treatment of different mental health disorders.

Mindstate’s target discovery and phenotypic screening platform Osmanthus is powered by human experience, combining natural history, natural language processing, and biochemical data in a predictive model that enables the precision design of modified conscious states.

Osmanthus combines natural history, biochemical data, and artificial intelligence to identify and validate patterns linking biochemical data to qualitative human reports of drug effects. Databases from human reports of the effects of various psychedelics over the last 50 years have provided crucial data for the Osmanthus platform’s natural history and computational AI techniques. Mindstate now uses the resulting pattern identification to prioritize its pipeline of primer/probe combinations for advancement to clinical trials. 

Mindstate is working on a robust database of phenomenological and biochemical data on psychedelic compounds: > 7,000 experience reports synthesized with assays of dozens of compounds against > 50 receptors, transporters, and ion channels.

For more on Mindstate Design Labs, visit their website here.

Read More